You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 22, 2024

~ Buy the DYANAVEL XR 5 (amphetamine; amphetamine aspartate/dextroamphetamine sulfate) Drug Profile, 2024 PDF Report in the Report Store ~

CLINICAL TRIALS PROFILE FOR DYANAVEL XR 5


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for DYANAVEL XR 5

Trial ID Title Status Sponsor Phase Start Date Summary
NCT03088267 ↗ Dyanavel® XR Extended-Release Oral Suspension in the Treatment of Children With ADHD: A Laboratory School Study Completed Tris Pharma, Inc. Phase 3 2017-02-11 This study was conducted to assess the efficacy and safety of DYANAVEL XR (amphetamine extended-release oral suspension, CII) for the treatment of symptoms of attention-deficit/hyperactivity disorder (ADHD) in children aged 6-12 years.
NCT03610464 ↗ Pharmacokinetic Study of DYANAVEL XR (Amphetamine) Extended-release Oral Suspension, in Children Aged 4 to 5 Years Completed Tris Pharma, Inc. Phase 4 2018-05-07 The objective of this study was to evaluate the plasma amphetamine concentration/time profile of amphetamine extended release oral suspension in children aged 4 to 5 years with attention-deficit/hyperactivity disorder, following a single 2.5 mg dose of amphetamine extended release oral suspension.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for DYANAVEL XR 5

Condition Name

Condition Name for DYANAVEL XR 5
Intervention Trials
Attention Deficit Hyperactivity Disorder 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for DYANAVEL XR 5
Intervention Trials
Attention Deficit Disorder with Hyperactivity 2
Hyperkinesis 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for DYANAVEL XR 5

Trials by Country

Trials by Country for DYANAVEL XR 5
Location Trials
United States 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for DYANAVEL XR 5
Location Trials
Florida 1
Nevada 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for DYANAVEL XR 5

Clinical Trial Phase

Clinical Trial Phase for DYANAVEL XR 5
Clinical Trial Phase Trials
Phase 4 1
Phase 3 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for DYANAVEL XR 5
Clinical Trial Phase Trials
Completed 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for DYANAVEL XR 5

Sponsor Name

Sponsor Name for DYANAVEL XR 5
Sponsor Trials
Tris Pharma, Inc. 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for DYANAVEL XR 5
Sponsor Trials
Industry 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.